IGC Pharma Inc (IGC)
| Market Cap | 33.96M |
| Revenue (ttm) | 1.35M |
| Net Income (ttm) | -13.00M |
| Shares Out | 75.64M |
| EPS (ttm) | -0.22 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 87,750 |
| Open | 0.462 |
| Previous Close | 0.450 |
| Day's Range | 0.441 - 0.462 |
| 52-Week Range | 0.250 - 0.910 |
| Beta | 1.30 |
| Analysts | Strong Buy |
| Price Target | 3.38 (+652.78%) |
| Earnings Date | Aug 8, 2024 |
About IGC
IGC Pharma, Inc., a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer’s disease. The company’s lead product is IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer’s; and TGR-63, IGC-1C, IGC-M3, and LMP in pre-clinical development. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland. [Read more]
Financial Performance
In 2023, IGC Pharma's revenue was $1.35 million, an increase of 47.64% compared to the previous year's $911,000. Losses were -$13.00 million, 13.0% more than in 2022.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for IGC stock is "Strong Buy." The 12-month stock price forecast is $3.38, which is an increase of 652.78% from the latest price.
News
IGC Pharma Announces Equity Analyst Coverage by Alliance Global Partners (AGP) with a "Buy" Recommendation and $3.50 Price Target
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Announces Equity Analyst Coverage by Alliance Global Partners (AGP) with a "Buy" Recommendation and $3.50 Price Target.
Preclinical Analyses of TGR-63 Demonstrate Blood-Brain Barrier Permeability and Safety Profile
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--Preclinical Analyses of TGR-63 Demonstrate Blood-Brain Barrier Permeability and Safety Profile.
IGC Pharma's TGR-63 Preclinical Results Show Substantial Reduction in Amyloid Plaque, a Key Hallmark of Alzheimer's Disease
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma's TGR-63 Preclinical Results Show Substantial Reduction in Amyloid Plaque, a Key Hallmark of Alzheimer's Disease.
IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets.
IGC Pharma Publishes Study in European Society of Medicine Investigating the Impact of CYP2C9 Genetic Polymorphism on Pharmacokinetics of Delta 9 Tetrahydrocannabinol
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Publishes Study in European Society of Medicine.
IGC Pharma Announces Patient Enrollment at Neurostudies in Phase 2 Trial Investigating IGC-AD1
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Announces Patient Enrollment at Neurostudies, Inc. in Phase 2 Trial Investigating IGC-AD1.
IGC Pharma to Attend BIO International Convention 2024
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma to Attend BIO International Convention 2024.
IGC-AD1's Interim Phase 2 Data Show a Reduction in Alzheimer's Agitation at Week Two
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC-AD1's Interim Phase 2 Data Show a Reduction in Alzheimer's Agitation at Week Two.
IGC Pharma Adds Advisor in Artificial Intelligence
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Adds Advisor in Artificial Intelligence.
IGC Pharma Announces $3 Million Unregistered Private Placement of its Common Stock
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Announces $3 Million Unregistered Private Placement of its Common Stock.
IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer's Agitation
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer's Agitation.
IGC PHARMA Announces its Participation at the Benzinga Virtual Healthcare Summit 2024
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC PHARMA Announces its Participation at the Benzinga Virtual Healthcare Summit 2024.
IGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer's Pipeline
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma (IGC)- Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer's Pipeline.
IGC Pharma Announces Equity Analyst Coverage by Ascendiant with a “Buy” Recommendation and $3.00 Price Target
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Ascendiant Coverage.
IGC Pharma Reports Third Quarter Fiscal 2024 Results
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Reports Third Quarter Fiscal 2024 Results.
IGC Pharma Announces TGR-63 Reduces Agitation in Alzheimer's Mouse Model
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--TGR-63 Reduces Agitation in Alzheimer's Mouse Model.
IGC Pharma Breakthrough: Preclinical Trial Data Shows TGR-63 Reduces Plaque in Alzheimer's
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Breakthrough - Preclinical Trial Data Shows TGR-63 Reduces Plaque in Alzheimer's.
IGC Pharma Activates ClinCloud, One of 12 Sites in Ongoing Phase 2b Alzheimer's Trial
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Activates ClinCloud, One of 12 Sites in Ongoing Phase 2b Alzheimer's Trial.
Patent Granted to IGC Pharma for Groundbreaking Drug Formulation to Treat Agitation in Alzheimer's
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--Patent Granted to IGC Pharma for Groundbreaking Drug Formulation to Treat Agitation in Alzheimer's.
IGC Pharma Announces Participation in Biotech Showcase and BioPartnering @ JPM Alongside the J.P. Morgan 41st Annual Healthcare Conference 2024
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Announces Participation in Biotech Showcase and BioPartnering @ JPM Alongside the J.P. Morgan 41st Annual Healthcare Conference 2024.
IGC Pharma Announces Collaboration to Integrate AI into Clinical Trials
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American: IGC) today announced an Artificial Intelligence (AI) collaboration with Los Andes University's Center for...
IGC Pharma Announces Master Agreement with Leading South American University to Advance AI Initiatives
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Announces Master Agreement with Leading South American University to Advance AI Initiatives.
IGC Pharma Reports Second Quarter Fiscal 2024 Results
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Reports Second Quarter Fiscal 2024 Results.
IGC Pharma Granted European Patent for Groundbreaking Cannabinoid-Based Pain Topical Relief Therapy
POTOMAC, Md.--(BUSINESS WIRE)-- #IGC--IGC Pharma Granted European Patent for Groundbreaking Cannabinoid-Based Pain Topical Relief Therapy.
IGC Pharma Reports First Quarter Results; Company Continues to Make Significant Progress Advancing Its Lead Alzheimer's Candidate Through Phase 2 Clinical Trials
POTOMAC, Md.--(BUSINESS WIRE)-- #IGC--IGC Pharma Reports First Quarter Results; Company Continues to Make Significant Progress Advancing Its Lead Alzheimer's Candidate.